日本新薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4516/E00931 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/04/08 | 日証協 | 541,957株 | -12.4% | 222,890株 | -30.77% | 475,953株 | -34.84% | 474,010株 | +42.11% |
2022/04/01 | 日証協 | 618,645株 | -8.73% | 321,953株 | -17.46% | 730,428株 | -3.02% | 333,557株 | +13.92% |
2022/03/25 | 日証協 | 677,829株 | +16.02% | 390,058株 | +279.13% | 753,146株 | +25% | 292,802株 | +6.51% |
2022/03/18 | 日証協 | 584,259株 | -3.43% | 102,882株 | -45.88% | 602,534株 | -23.68% | 274,906株 | -16.36% |
2022/03/11 | 日証協 | 605,004株 | +7.52% | 190,088株 | +0.84% | 789,471株 | +4.51% | 328,667株 | +69.48% |
2022/03/04 | 日証協 | 562,671株 | +13.33% | 188,500株 | +2.21% | 755,377株 | +4.06% | 193,921株 | +44.93% |
2022/02/25 | 日証協 | 496,486株 | +0.09% | 184,426株 | +30.29% | 725,929株 | +5.68% | 133,807株 | -61.49% |
2022/02/18 | 日証協 | 496,051株 | -16.17% | 141,551株 | +117.82% | 686,923株 | -5.5% | 347,444株 | +170.87% |
2022/02/10 | 日証協 | 591,713株 | -0.63% | 64,984株 | -53.48% | 726,889株 | +11.54% | 128,269株 | -1.57% |
2022/02/04 | 日証協 | 595,456株 | +5.85% | 139,684株 | -6.06% | 651,697株 | +9.27% | 130,315株 | -4.5% |
2022/01/28 | 日証協 | 562,527株 | +9.41% | 148,699株 | +134.36% | 596,431株 | +18.25% | 136,450株 | +74.55% |
2022/01/21 | 日証協 | 514,157株 | -1.11% | 63,449株 | -45.47% | 504,394株 | +0.92% | 78,171株 | +143.41% |
2022/01/14 | 日証協 | 519,926株 | -28.36% | 116,364株 | +162.33% | 499,791株 | -17.6% | 32,115株 | -58.13% |
2022/01/07 | 日証協 | 725,765株 | -2.46% | 44,358株 | -68.01% | 606,570株 | +9.53% | 76,708株 | +0.72% |
2021/12/30 | 日証協 | 744,104株 | 0% | 138,665株 | 0% | 553,773株 | 0% | 76,160株 | 0% |
2021/12/24 | 日証協 | 744,104株 | +14.74% | 138,665株 | -18.59% | 553,773株 | +5.08% | 76,160株 | +16.07% |
2021/12/17 | 日証協 | 648,521株 | +11.74% | 170,324株 | -0.79% | 527,003株 | +3.07% | 65,618株 | -11.5% |
2021/12/10 | 日証協 | 580,361株 | +14.22% | 171,680株 | -4.74% | 511,288株 | -1.95% | 74,145株 | -52.79% |
2021/12/03 | 日証協 | 508,093株 | +9.34% | 180,226株 | +84.45% | 521,446株 | +14.38% | 157,045株 | +191.75% |
※株式分割は考慮していませんのでご注意ください。
Page Top